Self-amplifying RNA COVID-19 vaccine.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 38608649.
- Also identified by DOI 10.1016/j.cell.2024.03.018.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In November 2023, Japan's Ministry of Health, Labour and Welfare granted regulatory approval of ARCT-154, a self-amplifying RNA COVID-19 vaccine developed by Arcturus Therapeutics. Clinical trials showed comparable safety and efficacy using a lower dose compared to the mRNA vaccine BNT162b2. To view this Bench-to-Bedside, open or download the PDF.
Medical subject headings
- COVID-19 Vaccines
- mRNA Vaccines